EichorEICHOR
Condition: Recurrent Or Metastatic Gastric Or Gastroesophageal Junction Synced from ClinicalTrials.gov · August 04, 2026

Recruiting studies: Recurrent Or Metastatic Gastric Or Gastroesophageal Junction

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesop
Phase 2 · 4 location(s) · Gilead Sciences · NCT07546812The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients
Phase 2 · 1 location(s) · Shanghai Zhongshan Hospital · NCT06587425Capeox Regimen Combined With Sintilimab and Bevacizumab for Gastric Cancer
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT05640609Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma
Phase 3 · 1 location(s) · Biotech Pharmaceutical Co., Ltd. · NCT05978050A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic So
Phase 2 · 119 location(s) · Daiichi Sankyo · NCT06330064
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.